{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:17:11Z","timestamp":1788185831803,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019751","name":"JSS Academy of Higher Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.intimp.2023.110464","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T23:12:10Z","timestamp":1687907530000},"page":"110464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Psoriasis and skin cancer \u2013 Is there a link?"],"prefix":"10.1016","volume":"121","author":[{"given":"Aayushi","family":"Balda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irshad","family":"Wani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsheel Fatima","family":"Roohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7538-0798","authenticated-orcid":false,"given":"K.L.","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Mehdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek PR","family":"Nadiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa","family":"Makkapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD Awaise Iqbal","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110464_b0005","unstructured":"Psoriasis - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/28846344\/ (accessed November 24, 2022)."},{"key":"10.1016\/j.intimp.2023.110464_b0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0015","unstructured":"Global report on psoriasis, (n.d.). https:\/\/apps.who.int\/iris\/handle\/10665\/204417 (accessed November 24, 2022)."},{"key":"10.1016\/j.intimp.2023.110464_b0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0025","unstructured":"Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/29462227\/ (accessed November 24, 2022)."},{"key":"10.1016\/j.intimp.2023.110464_b0030","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0035","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0040","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2023.110464_b0045","doi-asserted-by":"crossref","unstructured":"B.J. Nickoloff, J.Z. Qin, F.O. Nestle, Immunopathogenesis of psoriasis, Clinical Rev. Allergy Immunol. 33:1. 33 (2007) 45\u201356. 10.1007\/S12016-007-0039-2.","DOI":"10.1007\/s12016-007-0039-2"},{"key":"10.1016\/j.intimp.2023.110464_b0050","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1600-0625.2007.00629.x","article-title":"Immunopathogenesis of psoriasis","volume":"16","author":"Sabat","year":"2007","journal-title":"Exp Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0055","doi-asserted-by":"crossref","unstructured":"P. Gisondi, M. Talamonti, A. Chiricozzi, S. Piaserico, P. Amerio, A. Balato, F. Bardazzi, P. Calzavara Pinton, A. Campanati, A. Cattaneo, P. Dapavo, C. de Simone, V. Dini, M.C. Fargnoli, M.L. Flori, M. Galluzzo, C. Guarneri, C. Lasagni, F. Loconsole, A. lo Schiavo, P. Malagoli, G. Malara, S.R. Mercuri, M.L. Musumeci, L. Naldi, M. Papini, A. Parodi, C. Potenza, F. Prignano, F. Rongioletti, L. Stingeni, R. Tiberio, M. Venturini, L. Bianchi, A. Costanzo, F. Cusano, G. Girolomoni, A.M. Offidani, K. Peris, Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations, Dermatol Ther (Heidelb). 11 (2021) 235\u2013252. 10.1007\/S13555-020-00475-8\/TABLES\/5.","DOI":"10.1007\/s13555-020-00475-8"},{"key":"10.1016\/j.intimp.2023.110464_b0060","doi-asserted-by":"crossref","first-page":"e12806","DOI":"10.1111\/dth.12806","article-title":"HIV-associated psoriasis: Epidemiology, pathogenesis, and management","volume":"32","author":"Ceccarelli","year":"2019","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2023.110464_b0065","doi-asserted-by":"crossref","unstructured":"A. Kawada, T. Tezuka, Y. Nakamizo, H. Kimura, H. Nakagawa, M. Ohkido, A. Ozawa, A. Ohkawara, H. Kobayashi, S. Harada, A. Igarashi, A survey of psoriasis patients in Japan from 1982 to 2001, J. Dermatol. Sci. 31 (2003) 59\u201364. 10.1016\/S0923-1811(02)00142-1.","DOI":"10.1016\/S0923-1811(02)00142-1"},{"key":"10.1016\/j.intimp.2023.110464_b0070","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/j.1346-8138.2010.01145.x","article-title":"Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002\u20132008","volume":"38","author":"Takahashi","year":"2011","journal-title":"J. Dermatol."},{"issue":"2018","key":"10.1016\/j.intimp.2023.110464_b0075","first-page":"293","article-title":"Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research","volume":"45","author":"Ito","year":"2009","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0080","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/archdermatol.2010.186","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study","volume":"146","author":"Olivier","year":"2010","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0085","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jaad.2013.06.053","article-title":"Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors","volume":"69","author":"Miller","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0095","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and Obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.intimp.2023.110464_b0100","doi-asserted-by":"crossref","unstructured":"N.D. Loft, S. Vaengebjerg, L. Skov, Cancer risk in patients with psoriasis: should we be paying more attention? 16 (2020) 479\u2013492. 10.1080\/1744666X.2020.1754194.","DOI":"10.1080\/1744666X.2020.1754194"},{"key":"10.1016\/j.intimp.2023.110464_b0105","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaad.2016.09.047","article-title":"The risk of melanoma and hematologic cancers in patients with psoriasis","volume":"76","author":"Reddy","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0110","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jamadermatol.2020.1422","article-title":"Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa","volume":"156","author":"Jung","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0120","unstructured":"E. Shacter, S.A. Weitzman, Chronic inflammation and cancer, Oncology (Williston Park). 16 (2002) 217\u201326, 229; discussion 230. https:\/\/europepmc.org\/article\/med\/11866137 (accessed November 24, 2022)."},{"key":"10.1016\/j.intimp.2023.110464_b0125","doi-asserted-by":"crossref","unstructured":"G. Tchernev, C. Guarneri, V. Bevelacqua, U. Wollina, Carcinoma cuniculatum in course of etanercept: blocking autoimmunity but propagation of carcinogenesis? 27 (2014) 261\u2013266, 10.1177\/039463201402700213.","DOI":"10.1177\/039463201402700213"},{"key":"10.1016\/j.intimp.2023.110464_b0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clindermatol.2009.03.003","article-title":"Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0135","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/archdermatol.2012.1374","article-title":"Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis","volume":"148","author":"Leonardi-Bee","year":"2012","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0140","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/jdv.15177","article-title":"Position statement for the management of comorbidities in psoriasis","volume":"32","author":"Dauden","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0145","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jdv.12675","article-title":"An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors","volume":"29","author":"van L\u00fcmig","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1684\/ejd.2017.3032","article-title":"Reduced frequency of non-melanoma skin cancer in 72,739 patients with psoriasis: a retrospective study","volume":"27","author":"Paradisi","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0155","doi-asserted-by":"crossref","unstructured":"R. Beyaert, L. Beaugerie, G. van Assche, L. Brochez, J.C. Renauld, M. Viguier, V. Cocquyt, G. Jerusalem, J.P. Machiels, H. Prenen, P. Masson, E. Louis, F. de Keyser, Cancer risk in immune-mediated inflammatory diseases (IMID), Mol. Cancer 2013 12:1. 12 (2013) 1\u201312. 10.1186\/1476-4598-12-98.","DOI":"10.1186\/1476-4598-12-98"},{"key":"10.1016\/j.intimp.2023.110464_b0160","doi-asserted-by":"crossref","unstructured":"M.G. Borrello, L. Alberti, A. Fischer, D. Degl\u2019Innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, S. Pilotti, G. Cassinelli, P. Bressan, L. Fugazzola, A. Mantovani, M.A. Pierotti, Induction of a proinflammatory program in normal human thyrocytes by the RET\/PTC1 oncogene, Proc. Natl. Acad. Sci. U S A. 102 (2005) 14825\u201314830. 10.1073\/PNAS.0503039102\/SUPPL_FILE\/03039FIG6.PDF.","DOI":"10.1073\/pnas.0503039102"},{"key":"10.1016\/j.intimp.2023.110464_b0165","doi-asserted-by":"crossref","first-page":"11821","DOI":"10.1158\/0008-5472.CAN-07-0899","article-title":"Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer","volume":"67","author":"de Falco","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.110464_b0170","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2023.110464_b0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000000236","article-title":"Cytokines, IBD, and colitis-associated cancer","volume":"21","author":"Francescone","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2023.110464_b0180","unstructured":"Increased p53 Mutation Load in Noncancerous Colon Tissue from Ulcerative Colitis: A Cancer-prone Chronic Inflammatory Disease | Cancer Research | American Association for Cancer Research, (n.d.). https:\/\/aacrjournals.org\/cancerres\/article\/60\/13\/3333\/506396\/Increased-p53-Mutation-Load-in-Noncancerous-Colon (accessed November 24, 2022)."},{"key":"10.1016\/j.intimp.2023.110464_b0185","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.intimp.2023.110464_b0190","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"di Cesare","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0195","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2023.110464_b0200","doi-asserted-by":"crossref","unstructured":"S.P. Cannav\u00f2, G. Riso, M. Casciaro, E. di Salvo, S. Gangemi, Oxidative stress involvement in psoriasis: a systematic review, 53 (2019) 829\u2013840. 10.1080\/10715762.2019.1648800.","DOI":"10.1080\/10715762.2019.1648800"},{"key":"10.1016\/j.intimp.2023.110464_b0205","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ccell.2017.11.004","article-title":"Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis","volume":"32","author":"Canli","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2023.110464_b0210","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/jid.2012.456","article-title":"CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-\u03b3, IL-13, IL-17, and IL-22","volume":"133","author":"Hijnen","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2023.110464_b0220","first-page":"735","article-title":"Differential expression of cyclin D1, Ki-67, pRb, and p53 in psoriatic skin lesions and normal skin","volume":"17","author":"Kim","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2023.110464_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr1746","article-title":"Inflammation and breast cancer Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression","volume":"9","author":"DeNardo","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.intimp.2023.110464_b0230","doi-asserted-by":"crossref","unstructured":"A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, Nature 454:7203. 454 (2008) 436\u2013444. 10.1038\/nature07205.","DOI":"10.1038\/nature07205"},{"key":"10.1016\/j.intimp.2023.110464_b0235","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.15190\/d.2015.30","article-title":"Inflammation markers in cutaneous melanoma - edgy biomarkers for prognosis","volume":"3","author":"Neagu","year":"2015","journal-title":"Discoveries"},{"key":"10.1016\/j.intimp.2023.110464_b0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12325-019-01130-1","article-title":"Recognising skin cancer in primary care","volume":"37","author":"Jones","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.intimp.2023.110464_b0245","unstructured":"P. Gruber, M. Shah, P.M. Zito, Skin Cancer, StatPearls, 2017. http:\/\/europepmc.org\/books\/NBK441949 (accessed November 24, 2022)."},{"key":"10.1016\/j.intimp.2023.110464_b0250","doi-asserted-by":"crossref","unstructured":"K. Das, C.J. Cockerell, A. Patil, P. Pietkiewicz, M. Giulini, S. Grabbe, M. Goldust, Machine learning and its application in skin cancer, Int. J. Environ. Res. Public Health 18 (2021) 13409. 10.3390\/IJERPH182413409.","DOI":"10.3390\/ijerph182413409"},{"key":"10.1016\/j.intimp.2023.110464_b0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-016-0165-y","article-title":"Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"10.1016\/j.intimp.2023.110464_b0260","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/pcmr.12993","article-title":"Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines","volume":"34","author":"Campagna","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"issue":"2021","key":"10.1016\/j.intimp.2023.110464_b0265","first-page":"209","article-title":"Global cancer statistics GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2023.110464_b0270","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7150\/jca.37015","article-title":"Risk of non-melanoma skin cancer in patients with psoriasis: an updated evidence from systematic review with meta-analysis","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.intimp.2023.110464_b0275","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J.. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0280","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0285","first-page":"1059","article-title":"Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"18","author":"deShazo","year":"2019","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0290","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/jdv.13619","article-title":"Skin cancer in patients with psoriasis","volume":"30","author":"Egeberg","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0295","doi-asserted-by":"crossref","first-page":"491","DOI":"10.5603\/FHC.2012.0069","article-title":"Melanoma and other malignant skin cancers in psoriatic patients treated with phototherapy. Role of the p16 protein in psoriasis","volume":"50","author":"Szponar-Bojda","year":"2012","journal-title":"Folia Histochem. Cytobiol."},{"key":"10.1016\/j.intimp.2023.110464_b0300","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaad.2021.01.084","article-title":"Psoriasis and risk of cutaneous melanoma: a retrospective, comparative, registry-based cohort study","volume":"86","author":"Polesie","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0305","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0310","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjd.18887","article-title":"Methotrexate treatment for patients with psoriasis and risk of cutaneous melanoma: a nested case\u2013control study","volume":"183","author":"Polesie","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0315","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0320","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","article-title":"Malignant tumours and psoriasis: a follow-up study","volume":"140","author":"Frentz","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0325","doi-asserted-by":"crossref","unstructured":"A.O. Jensen, C. Svaerke, D. K\u00f6rmendin\u00e9 Farkas, A.B. Olesen, K. Kragballe, H.T. S\u00f8rensen, Atopic dermatitis and risk of skin cancer, Am. J. Clin. Dermatol. 13(1) (2012) 29\u201336. 10.2165\/11593280-000000000-00000.","DOI":"10.2165\/11593280-000000000-00000"},{"key":"10.1016\/j.intimp.2023.110464_b0330","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2340\/00015555-2637","article-title":"Risk of non-melanoma skin cancer in patients with atopic dermatitis treated with oral immunosuppressive drugs","volume":"97","author":"Garritsen","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.det.2018.07.009","article-title":"Skin cancer and immunosuppression","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.intimp.2023.110464_b0340","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol."},{"key":"#cr-split#-10.1016\/j.intimp.2023.110464_b0345.1","doi-asserted-by":"crossref","unstructured":"A. Jensen, H.F. Thomsen, M.C. Engebjerg, A.B. Olesen, S. Friis, M.R. Karagas, H.T. S\u00f8rensen, Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study, Brit. J. Cancer 2009 100","DOI":"10.1038\/sj.bjc.6604796"},{"key":"#cr-split#-10.1016\/j.intimp.2023.110464_b0345.2","unstructured":"(1) (2008) 200-205. 10.1038\/sj.bjc.6604796."},{"key":"10.1016\/j.intimp.2023.110464_b0350","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2340\/00015555-1753","article-title":"The risk of skin cancer in psoriasis patients treated with UVB therapy","volume":"94","author":"Osmancevic","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0360","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0365","doi-asserted-by":"crossref","unstructured":"V. di Lernia, L. Stingeni, V. Boccaletti, P.G. Calzavara Pinton, C. Guarneri, A. Belloni Fortina, M. Panzone, M. Corazza, I. Neri, S. Cambiaghi, C. Lasagni, E. Ficarelli, P. Gisondi, Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis 27 (2015) 395\u2013398, 10.3109\/09546634.2015.1120852.","DOI":"10.3109\/09546634.2015.1120852"},{"key":"10.1016\/j.intimp.2023.110464_b0370","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0140-6736(01)06179-7","article-title":"Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study","volume":"358","author":"Marcil","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.110464_b0375","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1600-0625.2009.01034.x","article-title":"Topical hydrocortisone, clobetasol propionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice","volume":"19","author":"Lerche","year":"2010","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0380","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jphotobiol.2004.09.010","article-title":"1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage","volume":"78","author":"de Haes","year":"2005","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.intimp.2023.110464_b0385","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.11124\/JBISRIR-2017-003393","article-title":"Long-term topical corticosteroid use and risk of skin cancer: asystematic review","volume":"16","author":"Ratib","year":"2018","journal-title":"JBI Database System Rev. Implement. Rep."},{"key":"10.1016\/j.intimp.2023.110464_b0390","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/djh118","article-title":"Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study","volume":"96","author":"S\u00f8rensen","year":"2004","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.intimp.2023.110464_b0395","doi-asserted-by":"crossref","unstructured":"S. Geller, H. Xu, M. Lebwohl, B. Nardone, M.E. Lacouture, M. Kheterpal, Malignancy risk and recurrence with psoriasis and its treatments: a concise update, Am. J. Clin. Dermatol. 19(3) (2017) 363\u2013375. 10.1007\/S40257-017-0337-2.","DOI":"10.1007\/s40257-017-0337-2"},{"key":"10.1016\/j.intimp.2023.110464_b0400","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-4632.2004.02186.x","article-title":"UVB phototherapy and skin cancer risk: a review of the literature","volume":"44","author":"Lee","year":"2005","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0405","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0410","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0415","doi-asserted-by":"crossref","unstructured":"M. Weischer, A. Blum, F. Eberhard, M. Ro\u00a8cken, R. Ro\u00a8cken, M. Berneburg, No Evidence for Increased Skin Cancer Risk in Psoriasis Patients Treated with Broadband or Narrowband UVB Phototherapy: A First Retrospective Study, Acta Derm Venereol. 84 (2004) 370\u2013374. Doi: 10.1080\/00015550410026948.","DOI":"10.1080\/00015550410026948"},{"key":"10.1016\/j.intimp.2023.110464_b0420","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1523-1747.ep12522663","article-title":"The PUVA lentigo: An analysis of predisposing factors","volume":"81","author":"Rhodes","year":"1983","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0425","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2023.110464_b0430","doi-asserted-by":"crossref","unstructured":"R. Obert, S.S. Tern, H.T.N. Ichols, H. v \u00c4kev\u00e4, Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA), 336 (1997) 1041\u20131045. 10.1056\/NEJM199704103361501.","DOI":"10.1056\/NEJM199704103361501"},{"key":"10.1016\/j.intimp.2023.110464_b0435","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study","volume":"66","author":"Stern","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0440","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/phpp.12443","article-title":"Risk of skin cancer in psoriasis patients receiving long-term narrowband ultraviolet phototherapy: results from a Taiwanese population-based cohort study","volume":"35","author":"Lin","year":"2019","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.intimp.2023.110464_b0445","doi-asserted-by":"crossref","unstructured":"A. Maiorino, C. de Simone, F. Perino, G. Caldarola, K. Peris, Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy, 27 (2016) 443\u2013447. 10.3109\/09546634.2015.1133882.","DOI":"10.3109\/09546634.2015.1133882"},{"key":"10.1016\/j.intimp.2023.110464_b0450","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.110464_b0455","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","article-title":"The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials","volume":"12","author":"Leonardi","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0465","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor \u03b1 inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2023.110464_b0470","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2023.110464_b0475","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3389\/fonc.2021.687432","article-title":"Incidence of skin cancer in patients with chronic inflammatory cutaneous diseases on targeted therapies: a systematic review and meta-analysis of observational studies","volume":"11","author":"Crisafulli","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2023.110464_b0480","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch. Dermatol Res."},{"key":"10.1016\/j.intimp.2023.110464_b0485","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1684\/ejd.2020.3860","article-title":"Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer","volume":"30","author":"Kamiya","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110464_b0490","unstructured":"L. Mastorino, N. Siliquini, G. Avallone, M. Ortoncelli, P. Quaglino, P. Dapavo, S. Ribero, Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis, Pagepress.Org. (n.d.). 10.4081\/dr.2022.9282."},{"key":"10.1016\/j.intimp.2023.110464_b0495","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2023.110464_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110464_b0505","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2023.110464_b0510","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.110464_b0515","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.intimp.2023.110464_b0520","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","article-title":"An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.intimp.2023.110464_b0525","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ptr.5316","article-title":"Review of clinical pharmacology of Aloe vera L. in the treatment of psoriasis","volume":"29","author":"Miroddi","year":"2015","journal-title":"Phytother. Res."},{"key":"10.1016\/j.intimp.2023.110464_b0530","doi-asserted-by":"crossref","unstructured":"R. Article, A. Mj, S. Tr, P. Bj, Anti microbial activity of different dosage forms of Bakuchi (Psoralea corylifolia Linn.) taila, An Ayurvedic formulation, Int. J. Ayurvedic Med. 6 (2015) 232\u2013236. http:\/\/ijam.co.in (accessed January 9, 2023).","DOI":"10.47552\/ijam.v6i3.637"},{"key":"10.1016\/j.intimp.2023.110464_b0535","doi-asserted-by":"crossref","unstructured":"S.L. Badole, B.P. Pimple, Pongamia pinnata (Linn.) used in skin disease, Bioactive Dietary Factors Plant Extracts Dermatol. (2013) 471\u2013473. 10.1007\/978-1-62703-167-7_44\/COVER.","DOI":"10.1007\/978-1-62703-167-7_44"},{"key":"10.1016\/j.intimp.2023.110464_b0540","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.phymed.2017.07.001","article-title":"Neem (Azadirachta indica): an Indian traditional panacea with modern molecular basis","volume":"34","author":"Gupta","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2023.110464_b0545","unstructured":"S. Singh, B. Kumar, D. Singh Baghel, A. Kumar, D. Singh, Phytochemicals: An approach for psoriasis lozenges for emesis view project ayurveda view project PHYTOCHEMICALS: AN APPROACH FOR PSORIASIS, Int. J. Res. Anal. Rev. (2019). www.ijrar.org (accessed January 9, 2023)."},{"key":"10.1016\/j.intimp.2023.110464_b0550","doi-asserted-by":"crossref","unstructured":"M. Khan Yousufi, To study antibacterial activity of allium sativum, zingiber officinale and allium cepa by Kirby-Bauer method, IOSR J. Pharm. Biol. Sci. (IOSR-JPBS. 4 (n.d.) 6\u201308. www.iosrjournals.org (accessed January 9, 2023).","DOI":"10.9790\/3008-0450608"},{"key":"10.1016\/j.intimp.2023.110464_b0555","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2011.e4","article-title":"Garlic in dermatology","volume":"3","author":"Pazyar","year":"2011","journal-title":"Dermatol. Rep."},{"key":"10.1016\/j.intimp.2023.110464_b0560","first-page":"69","article-title":"Phytotherapeutic properties of milk thistle seeds: an overview","volume":"1","author":"Bhattacharya","year":"2011","journal-title":"J. Adv. Pharm. Educ. Res."},{"key":"10.1016\/j.intimp.2023.110464_b0565","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1365-2621.2006.01417.x","article-title":"Nutritional value, functional properties and nutraceutical applications of black cumin (Nigella sativa L.): an overview","volume":"42","author":"Ramadan","year":"2007","journal-title":"Int. J. Food Sci. Technol."},{"key":"10.1016\/j.intimp.2023.110464_b0570","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jtcme.2015.08.006","article-title":"A case series of the effects of a novel composition of a traditional natural preparation for the treatment of psoriasis","volume":"6","author":"Michalsen","year":"2016","journal-title":"J. Tradit. Complement. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:00:47Z","timestamp":1761588047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923007877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":113,"alternative-id":["S1567576923007877"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110464","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis and skin cancer \u2013 Is there a link?","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110464"}}